Expression of cancer/testis antigens is correlated with improved survival in glioblastoma

Oncotarget

Volumn 4, Issue 4, 2013, Pages 636-646

  Freitas, Marcelo Roberto Pereira ^a   Malheiros, Suzana Maria Fleury ^a   Stávale, João Norberto ^a   Biassi, Thais Priscila ^a   Zamunér, Fernando Tadeu ^a   Begnami, Maria Dirlei Ferreira de Souza ^b   Soares, Fernando Augusto ^b   Vettore, Andre Luíz ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Brain cancer; Cancer Testis antigens; CTA expression; Gbm; Glioblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER TESTIS ANTIGEN; MESSENGER RNA; PROTEIN CTCFL; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACTL8 GENE; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CTCFL GENE; FEMALE; GENE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OIP5 GENE; OVERALL SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; XAGE3 GENE;

EID: 84879155856     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.950     Document Type: Article

References (44)

1. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005; 352(10):987-996.
2. Grauer OM, Wesseling P and Adema GJ. Immunotherapy of diffuse gliomas: biological background, current status and future developments. Brain pathology. 2009; 19(4):674-693.
3. Mitchell DA, Fecci PE and Sampson JH. Immunotherapy of malignant brain tumors. Immunological reviews. 2008; 222:70-100.
4. Caballero OL and Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer science. 2009; 100(11):2014-2021.
5. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, Lehvaslaiho M, Carninci P, Hayashizaki Y, Jongeneel CV, Simpson AJ, Old LJ, et al. Genome-wide analysis of cancer/testis gene expression. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(51):20422-20427.
6. Scanlan MJ, Simpson AJ and Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer immunity. 2004; 4:1.
7. CTDatabase
8. Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, Nicolay HJ, Sigalotti L and Maio M. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Molecular oncology. 2011; 5(2):164-182.
9. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuno MA, Richardson JE, Fan X, Ji J, Chu RM, Bender JG, Hawkins ES, Patil CG, Black KL and Yu JS. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer immunology, immunotherapy: CII. 2012.
10. Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F and Ashley DM. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clinical cancer research: an official journal of the American Association for Cancer Research. 1999; 5(2):335-341.
11. Syed ON, Mandigo CE, Killory BD, Canoll P and Bruce JN. Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia. 2012; 19(7):1016-1021.
12. Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, Morton DL and Hoon DS. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. The American journal of pathology. 1997; 150(6):2143-2152.
13. Lee MH, Son EI, Kim E, Kim IS, Yim MB and Kim SP.Expression of cancer-testis genes in brain tumors. Journal of Korean Neurosurgical Society. 2008; 43(4):190-193.
14. Ueda R, Kinoshita E, Ito R, Kawase T, Kawakami Y and Toda M. Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6. International journal of cancer Journal international du cancer. 2008; 122(10):2274-2279.
15. Gao F, You T, Lu JY and Wang YJ. [Research on the expression of cancer associated gene in the intracranial tumors]. Sichuan da xue xue bao Yi xue ban = Journal of Sichuan University Medical science edition. 2006; 37(3):424-426.
16. Sahin U, Tureci O, Chen YT, Seitz G, Villena-Heinsen C, Old LJ and Pfreundschuh M. Expression of multiple cancer/ testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. International journal of cancer Journal international du cancer. 1998; 78(3):387-389.
17. Emens LA and Jaffee EM. Cancer vaccines: an old idea comes of age. Cancer biology & therapy. 2003; 2(4 Suppl 1):S161-168.
18. Cheever MA and Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(11):3520-3526.
19. Traynor K. Ipilimumab approved for metastatic melanoma. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists. 2011; 68(9):768.
20. Sahin U, Koslowski M, Tureci O, Eberle T, Zwick C, Romeike B, Moringlane JR, Schwechheimer K, Feiden W and Pfreundschuh M. Expression of cancer testis genes in human brain tumors. Clinical cancer research: an official journal of the American Association for Cancer Research. 2000; 6(10):3916-3922.
21. Natsume A, Wakabayashi T, Tsujimura K, Shimato S, Ito M, Kuzushima K, Kondo Y, Sekido Y, Kawatsura H, Narita Y and Yoshida J. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. International journal of cancer Journal international du cancer. 2008; 122(11):2542-2553.
22. Tureci O, Chen YT, Sahin U, Gure AO, Zwick C, Villena C, Tsang S, Seitz G, Old LJ and Pfreundschuh M. Expression of SSX genes in human tumors. International journal of cancer Journal international du cancer. 1998; 77(1):19-23.
23. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K and Karpf AR. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer immunity. 2007; 7:21.
24. Risinger JI, Chandramouli GV, Maxwell GL, Custer M, Pack S, Loukinov D, Aprelikova O, Litzi T, Schrump DS, Murphy SK, Berchuck A, Lobanenkov V and Barrett JC. Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13(6):1713-1719.
25. Koinuma J, Akiyama H, Fujita M, Hosokawa M, Tsuchiya E, Kondo S, Nakamura Y and Daigo Y. Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis. Cancer science. 2012; 103(3):577-586.
26. Chun HK, Chung KS, Kim HC, Kang JE, Kang MA, Kim JT, Choi EH, Jung KE, Kim MH, Song EY, Kim SY, Won M and Lee HG. OIP5 is a highly expressed potential therapeutic target for colorectal and gastric cancers. BMB reports. 2010; 43(5):349-354.
27. Oba-Shinjo SM, Caballero OL, Jungbluth AA, Rosemberg S, Old LJ, Simpson AJ and Marie SK. Cancer-testis (CT) antigen expression in medulloblastoma. Cancer immunity. 2008; 8:7.
28. Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, Hoda SA, Simpson AJ, Old LJ, Caballero O and Neville AM. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PloS one. 2011; 6(3):e17876.
29. Chen YT, Chadburn A, Lee P, Hsu M, Ritter E, Chiu A, Gnjatic S, Pfreundschuh M, Knowles DM and Old LJ. Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(7):3093-3098.
30. Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y and et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. International journal of cancer Journal international du cancer. 1995; 63(3):375-380.
31. Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungbluth A, Ritter G, Chen YT, Stockert E, Tsushima T, Kumon H, Old LJ and Nakayama E. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer research. 2001; 61(12):4671-4674.
32. Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M and Maio M. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer research. 2004; 64(24):9167-9171.
33. De Smet C, Loriot A and Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells. Molecular and cellular biology. 2004; 24(11):4781-4790.
34. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V, Figg WD, Murgo AJ and Steinberg SM. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(19):5777-5785.
35. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J and Rosenberg SA. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer research. 1994; 54(7):1766-1771.
36. Kawakami Y, Fujita T, Matsuzaki Y, Sakurai T, Tsukamoto M, Toda M and Sumimoto H. Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer science. 2004; 95(10):784-791.
37. Ohgaki H and Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. Journal of neuropathology and experimental neurology. 2005; 64(6):479-489.
38. Hegi ME, Diserens AC, Gorlia T, Hamou MF, De Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC and Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England journal of medicine. 2005; 352(10):997-1003.
39. Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS, Chauffaille ML, Andriolo A, Caballero OL, Zago MA and Colleoni GW. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer immunity. 2008; 8:2.
40. Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC and Resnick MB. Expression of the MAGE-A4 and NYESO-1 cancer-testis antigens in serous ovarian neoplasms. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003; 9(17):6453-6460.
41. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ and Altorki NK. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(22):8055-8062.
42. Cuffel C, Rivals JP, Zaugg Y, Salvi S, Seelentag W, Speiser DE, Lienard D, Monnier P, Romero P, Bron L and Rimoldi D. Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. International journal of cancer Journal international du cancer. 2011; 128(11):2625-2634.
43. Jung EJ, Kim MA, Lee HS, Yang HK, Lee YM, Lee BL and Kim WH. Expression of family A melanoma antigen in human gastric carcinoma. Anticancer research. 2005; 25(3B):2105-2111.
44. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ and Jungbluth AA. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(18):5442-5447.